Supplementary Figure 6 from Inhibition of Monocarboxylate Transporter-1 (MCT1) by AZD3965 Enhances Radiosensitivity by Reducing Lactate Transport

Bola, Becky M.; Chadwick, Amy L.; Michopoulos, Filippos; Blount, Kathryn G.; Telfer, Brian A.; Williams, Kaye J.; Smith, Paul D.; Critchlow, Susan E.; Stratford, Ian J.

doi:10.1158/1535-7163.22502370.v1

15357163mct131091-sup-124659_1_supp_2543472_n81347.docx (822.92 kB)

Supplementary Figure 6 from Inhibition of Monocarboxylate Transporter-1 (MCT1) by AZD3965 Enhances Radiosensitivity by Reducing Lactate Transport

journal contribution

posted on 2023-04-03, 14:26 authored by Becky M. Bola, Amy L. Chadwick, Filippos Michopoulos, Kathryn G. Blount, Brian A. Telfer, Kaye J. Williams, Paul D. Smith, Susan E. Critchlow, Ian J. Stratford

This file shows IHC slides of H526 tumors taken from mice treated with or without AZD3965 and stained for MCT4 or CD31 expression.

History

ARTICLE ABSTRACT

Inhibition of the monocarboxylate transporter MCT1 by AZD3965 results in an increase in glycolysis in human tumor cell lines and xenografts. This is indicated by changes in the levels of specific glycolytic metabolites and in changes in glycolytic enzyme kinetics. These drug-induced metabolic changes translate into an inhibition of tumor growth in vivo. Thus, we combined AZD3965 with fractionated radiation to treat small cell lung cancer (SCLC) xenografts and showed that the combination provided a significantly greater therapeutic effect than the use of either modality alone. These results strongly support the notion of combining MCT1 inhibition with radiotherapy in the treatment of SCLC and other solid tumors. Mol Cancer Ther; 13(12); 2805–16. ©2014 AACR.